1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

25 Aug 2020
Admin
News Article

Thermo Fisher Inks Cdx Agreement With Hengrui Therapeutics

Thermo Fisher Scientific Has Signed A Companion Diagnostic (Cdx) Agreement With Hengrui Therapeutics, Inc. (Hti), A Us Subsidiary Of Chinese Pharmaceutical Company Jiangsu Hengrui Medicine (Jhm), To Develop A Cdx That Will Leverage The Oncomine Precision Assay, Which Runs On The New Ion Torrent Genexus System. Once Commercialized, The Cdx Will Be Used To Identify Non-Small Cell Lung Cancer (Nsclc) Patients Who May Be Eligible For Pyrotinib, Jhm'S Novel, Irreversible Pan-Her2 Tyrosine Kinase Inhibitor.Under The Terms Of The Agreement, Thermo Fisher Will Retain Rights To Commercialize The Test Globally And Will Seek Approval From Regulatory Agencies. The Company Has Previously Announced A Cdx Agreement That Also Leverages The Oncomine Precision Assay For The Genexus System. In June The Fda Granted The Assay Breakthrough Device Designation To Identify Isocitrate Dehydrogenase 1 And 2 (Idh1 And Idh2) Mutations In Low-Grade Glioma Patients.The Oncomine Precision Assay Can Detect More Than 50 Cancer-Related Biomarkers From Formalin-Fixed Paraffin-Embedded (Ffpe) Tumor Tissues Or Liquid Biopsy Specimens. It Is Designed To Run On The Genexus System, A First-Of-Its-Kind Ngs Platform That Features An Automated Workflow With A One-Day Turnaround Time And The Lowest Sample Requirements On The Market For Detection Of Both Dna And Rna Variants. Currently, The Integrated Sequencer And Assay Are Labeled For Research Use Only.

Let’s apply Data-Driven Pricing to Your APIs

Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.

Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.

Start using market intelligence today and allow yourself to be in control in the API market.

Check it out today and make more informed sourcing decisions! Learn More!